➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
AstraZeneca
Boehringer Ingelheim
Moodys
Merck

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Litigation Details for DIVX, LLC v. Netflix, Inc. (C.D. Cal. 2019)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

DIVX, LLC v. Netflix, Inc. (C.D. Cal. 2019)

Small Molecule Drugs cited in DIVX, LLC v. Netflix, Inc.

Details for DIVX, LLC v. Netflix, Inc. (C.D. Cal. 2019)

Date Filed Document No. Description Snippet Link To Document
2020-04-22 100 Protective Order 2.13 “Patents-in-Suit” means U.S. Patent Nos. 7,295,673; 8,139,651; 18 8,472,792; 9,184,920; 9,270,720…any patent application related by claim of priority to any of the Patents- 8 in-Suit or patents relating…any of the Patents-in-Suit or patents relating to the field of the invention 11 of the Patents-in-Suit,…preceding five years, and (6) identifies 26 any patents or patent applications in which the Expert is identified…the invention of the Patents-in-Suit, including 9 but not limited to such patents assigned to DivX, Netflix External link to document
2020-04-27 102 Response in Opposition to Motion 10 U.S. Patent No. 9,270,720 (Dkt. 60-5) ’720 patent or ’720 R OBINS K APLAN… 12 U.S. Patent No. 10,225,588 (Dkt. 60-8) ’588 patent or ’588 … Netflix adopted DivX’s patented 10 technologies and leveraged…challenges to DivX’s patents will never 10 completely resolve…Notably, the patent owner in ASCII initiated the USPTO 10 proceedings External link to document
2020-05-11 106 Stay Case the completion of co-pending patent office proceedings. See ASCII, 844 F. Supp. at 1380. Second, and… 2020 September 2020 10,225,588 Yes Yes …. STD Entm’t USA, Inc., 844 F. Supp. 1378, 1380 (N.D. Cal. 1994). CV-90 (10/08) …infringement for that asserted patent.” Netflix Mot. 1 n.1. CV-90 (10/08) …defend its patents with objective considerations of non- obviousness. CV-90 (10/08) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKinsey
AstraZeneca
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.